An elderly case of paraneoplastic anti-NMDA receptor encephalitis associated with large cell neuroendocrine carcinoma of the lung.
Immunohistochemistry
Large cell neuroendocrine carcinoma
Paraneoplastic anti-NMDA receptor encephalitis
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
12 Jul 2024
12 Jul 2024
Historique:
received:
12
06
2023
accepted:
01
07
2024
medline:
13
7
2024
pubmed:
13
7
2024
entrez:
12
7
2024
Statut:
epublish
Résumé
Recent studies have suggested that N-methyl-D-aspartate (NMDA) receptors are involved in the cell proliferation in several tumors. However, there have been no reports demonstrating the expression of NR1 subunit of the NMDA receptor in large cell neuroendocrine carcinoma (LCNEC). Here, we report the first elderly case of paraneoplastic anti-NMDA receptor encephalitis associated with LCNEC of the lung with NR1 expression. Of note, NR1 subunit expression in the tumor cells of the present case was confirmed by immunohistochemistry (IHC). Radiation therapy and immunotherapies, such as corticosteroids and intravenous immunoglobulin (IVIG), shrank the tumors and improved neurological symptoms in the present case. Additionally, we also confirmed the expression of NR1 in the tumor cells obtained from three other cases with LCNEC of the lung at our hospital by IHC. Our IHC results indicate that LCNEC generally expresses NR1 subunit and NMDA receptor may be involved in the tumor development and growth.
Sections du résumé
BACKGROUND
BACKGROUND
Recent studies have suggested that N-methyl-D-aspartate (NMDA) receptors are involved in the cell proliferation in several tumors. However, there have been no reports demonstrating the expression of NR1 subunit of the NMDA receptor in large cell neuroendocrine carcinoma (LCNEC).
CASE PRESENTATION
METHODS
Here, we report the first elderly case of paraneoplastic anti-NMDA receptor encephalitis associated with LCNEC of the lung with NR1 expression. Of note, NR1 subunit expression in the tumor cells of the present case was confirmed by immunohistochemistry (IHC). Radiation therapy and immunotherapies, such as corticosteroids and intravenous immunoglobulin (IVIG), shrank the tumors and improved neurological symptoms in the present case. Additionally, we also confirmed the expression of NR1 in the tumor cells obtained from three other cases with LCNEC of the lung at our hospital by IHC.
CONCLUSION
CONCLUSIONS
Our IHC results indicate that LCNEC generally expresses NR1 subunit and NMDA receptor may be involved in the tumor development and growth.
Identifiants
pubmed: 38997707
doi: 10.1186/s12890-024-03137-z
pii: 10.1186/s12890-024-03137-z
doi:
Substances chimiques
Receptors, N-Methyl-D-Aspartate
0
NR1 NMDA receptor
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
336Informations de copyright
© 2024. The Author(s).
Références
Malenka RC, Nicoll RA. Long-term potentiation–a decade of progress? Sci (New York N Y). 1999;285:1870–4.
doi: 10.1126/science.285.5435.1870
Hajdú T, Juhász T, Szűcs-Somogyi C, Rácz K, Zákány R. NR1 and NR3B composed intranuclear N-methyl-d-aspartate receptor complexes in human melanoma cells. Int J Mol Sci 2018;19.
North WG, Gao G, Jensen A, Memoli VA, Du J. NMDA receptors are expressed by small-cell lung cancer and are potential targets for effective treatment. Clin Pharmacology: Adv Appl. 2010;2:31–40.
Stepulak A, Rola R, Polberg K, Ikonomidou C. Glutamate and its receptors in cancer. J Neural Transmission (Vienna Austria: 1996). 2014;121:933–44.
doi: 10.1007/s00702-014-1182-6
Yi H, Talmon G, Wang J. Glutamate in cancers: from metabolism to signaling. J Biomedical Res. 2019;34:260–70.
doi: 10.7555/JBR.34.20190037
Burket JA, Benson AD, Tang AH, Deutsch SI. NMDA receptor activation regulates sociability by its effect on mTOR signaling activity. Prog Neuro-psychopharmacol Biol Psychiatry. 2015;60:60–5.
doi: 10.1016/j.pnpbp.2015.02.009
Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7:1091–8.
doi: 10.1016/S1474-4422(08)70224-2
pubmed: 18851928
pmcid: 2607118
Kobayashi A, Yahata T, Nanjo S, et al. Rapidly progressing large-cell neuroendocrine carcinoma arising from the uterine corpus: a case report and review of the literature. Mol Clin Oncol. 2017;6:881–5.
doi: 10.3892/mco.2017.1229
pubmed: 28588782
pmcid: 5451872
Gozzard P, Woodhall M, Chapman C, et al. Paraneoplastic neurologic disorders in small cell lung carcinoma: a prospective study. Neurology. 2015;85:235–9.
doi: 10.1212/WNL.0000000000001721
pubmed: 26109714
pmcid: 4516293
Kobayashi Y, Sato M, Kinoshita M, et al. An Elderly Case of paraneoplastic Anti-NMDA receptor Encephalitis Associated with small-cell Lung Cancer expressing NR1 subunits. Intern Med (Tokyo Japan). 2020;59:2307–9.
doi: 10.2169/internalmedicine.4860-20
Afanasiev V, Brechemier ML, Boisseau W, et al. Anti-NMDA receptor antibody encephalitis and neuroendocrine pancreatic tumor: causal link? Neurology. 2016;87:112–3.
doi: 10.1212/WNL.0000000000002809
pubmed: 27281530
pmcid: 4932238
Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10:63–74.
doi: 10.1016/S1474-4422(10)70253-2
pubmed: 21163445
pmcid: 3158385
Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12:157–65.
doi: 10.1016/S1474-4422(12)70310-1
pubmed: 23290630
pmcid: 3563251